A Study of Adjuvant Melanoma Stakeholder Treatment Preferences

Bristol-Myers Squibb294 enrolled

Overview

The purpose of this study is to understand the trade-offs that participants with surgically treated melanoma would be willing to make among key features and outcomes of adjuvant anti-cancer treatments or no adjuvant treatment / observation.

Study Type

OBSERVATIONAL

Enrollment

294

Conditions

Melanoma

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Self-reported medical diagnosis of stage II or stage III melanoma * Have been resected (had surgery) for their melanoma within 12 months prior to study participation Exclusion Criteria: * Self-reported stage IIa * Self-reported recurrence of melanoma after surgery Other protocol-defined inclusion/exclusion criteria apply

Locations (1)

Local Institution

Melbourne, Victoria, Australia

Outcomes

Primary Outcomes

Preference weights or utilities (a measure of relative preference; on a continuous variable scale) for each treatment attribute level based on responses to the Discrete Choice Experiment (DCE) choice tasks

Time frame: At Baseline

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.